Diamonds and Dogs
Centene (CNC) jumped 5% to a six month high following better than expected earnings while also giving in line guidance. Earnings were helped by growth in its Obamacare individual business and along with the health insurer's efforts to turn around recently acquired Health Net. Early indications suggest if Obamacare is completely repealed and replaced the process may take several years and include a transition plan designed to minimize, if any, disruption to states or subsidized populations. Cantor Fitzgerald upgraded the stock to an overweight with a $85 price target.
Another CEO bites the dust. Teva Pharma (TEVA) dropped 6% to a new 52 week low after CEO, Erez Vigodman stepped down, making this the second high-profile management shake-up following the announcement of Siggi Olafsson's departure in December. Things have gone from bad to worse for Teva as the U.S. District Court ruled in favor of the TEva's competitor increasing likelihood of MNTA/Sandoz launching a generic version to TEVA's Copaxone 40mg Teva has also backed away from its long-term guidance issued in July.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.